Lazard Asset Management LLC bought a new stake in Cutera, Inc. (NASDAQ:CUTR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 8,359 shares of the medical device company’s stock, valued at approximately $379,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. California State Teachers Retirement System grew its holdings in Cutera by 1.3% in the 2nd quarter. California State Teachers Retirement System now owns 23,405 shares of the medical device company’s stock valued at $606,000 after buying an additional 300 shares during the last quarter. Nationwide Fund Advisors grew its holdings in Cutera by 8.4% in the 2nd quarter. Nationwide Fund Advisors now owns 7,216 shares of the medical device company’s stock valued at $187,000 after buying an additional 561 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Cutera by 12.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,479 shares of the medical device company’s stock valued at $297,000 after buying an additional 1,230 shares during the last quarter. Legal & General Group Plc grew its holdings in Cutera by 69.6% in the 3rd quarter. Legal & General Group Plc now owns 3,600 shares of the medical device company’s stock valued at $149,000 after buying an additional 1,477 shares during the last quarter. Finally, American International Group Inc. grew its holdings in Cutera by 19.4% in the 4th quarter. American International Group Inc. now owns 10,589 shares of the medical device company’s stock valued at $480,000 after buying an additional 1,724 shares during the last quarter. 95.29% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Shares of Cutera, Inc. (NASDAQ CUTR) opened at $53.30 on Wednesday. Cutera, Inc. has a 52-week low of $18.50 and a 52-week high of $54.25. The company has a market capitalization of $701.06, a P/E ratio of 66.58, a price-to-earnings-growth ratio of 1.10 and a beta of 0.51.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Wednesday, February 14th. The medical device company reported $0.42 EPS for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.09. Cutera had a return on equity of 18.31% and a net margin of 19.80%. The company had revenue of $47.60 million during the quarter, compared to the consensus estimate of $43.96 million. During the same quarter last year, the company earned $0.30 EPS. The company’s quarterly revenue was up 25.6% on a year-over-year basis. equities analysts expect that Cutera, Inc. will post 1.1 earnings per share for the current year.

In other Cutera news, EVP Larry Laber sold 5,843 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $45.35, for a total value of $264,980.05. Following the completion of the sale, the executive vice president now owns 79,463 shares in the company, valued at approximately $3,603,647.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David B. Apfelberg sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $47.40, for a total value of $47,400.00. Following the completion of the sale, the director now owns 8,259 shares of the company’s stock, valued at approximately $391,476.60. The disclosure for this sale can be found here. Insiders sold a total of 14,018 shares of company stock valued at $637,766 in the last quarter. Corporate insiders own 3.30% of the company’s stock.

A number of research firms have issued reports on CUTR. Stephens began coverage on Cutera in a report on Tuesday. They issued an “overweight” rating and a $60.00 target price on the stock. Zacks Investment Research lowered Cutera from a “hold” rating to a “sell” rating in a report on Tuesday, December 26th. Gabelli reaffirmed a “buy” rating on shares of Cutera in a report on Friday, February 16th. Finally, BidaskClub raised Cutera from a “hold” rating to a “buy” rating in a report on Tuesday, December 12th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $45.00.

ILLEGAL ACTIVITY NOTICE: “8,359 Shares in Cutera, Inc. (CUTR) Purchased by Lazard Asset Management LLC” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/03/14/8359-shares-in-cutera-inc-cutr-purchased-by-lazard-asset-management-llc.html.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Want to see what other hedge funds are holding CUTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cutera, Inc. (NASDAQ:CUTR).

Institutional Ownership by Quarter for Cutera (NASDAQ:CUTR)

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.